BBR	NNP	O
2778	CD	O
was	VBD	B
synthesized	VBN	O
and	CC	B
initially	RB	O
characterized	VBN	O
in	IN	O
vitro	NN	O
for	IN	O
tumor	NN	O
cell	NN	O
cytotoxicity	NN	O
and	CC	B
mechanism	NN	O
of	IN	B
action	NN	O
by	IN	O
studies	NNS	B
at	IN	O
the	DT	B
Boehringer	NNP	O
Mannheim	NNP	O
Italia	NNP	O
Research	NNP	O
Center	NNP	O
,	,	B
Monza	NNP	O
,	,	B
and	CC	I
University	NNP	O
of	IN	B
Vermont	NNP	O
,	,	B
Burlington	NNP	O
.	.	O

Other	JJ	B
studies	NNS	I
have	VBP	B
been	VBN	I
completed	VBN	O
at	IN	O
the	DT	B
University	NNP	O
of	IN	B
Texas	NNP	O
M.	NNP	O
D.	NNP	O
Anderson	NNP	O
Cancer	NNP	O
Center	NNP	O
,	,	B
Houston	NNP	O
,	,	B
the	DT	I
Istituto	NNP	O
Nazionale	NNP	O
Tumori	NNP	O
,	,	B
Milan	NNP	O
,	,	B
and	CC	I
the	DT	B
University	NNP	O
of	IN	B
Padua	NNP	O
.	.	O

In	IN	O
the	DT	B
search	NN	O
for	IN	O
novel	NN	O
heteroanalogs	NNS	O
of	IN	B
anthracenediones	NNS	O
,	,	B
it	PRP	I
was	VBD	B
selected	VBN	O
as	IN	O
the	DT	B
most	RBS	I
promising	JJ	O
compound	NN	O
.	.	O

Toxicological	JJ	O
studies	NNS	B
indicated	VBD	O
that	IN	O
BBR	NNP	O
2778	CD	O
was	VBD	B
not	RB	I
cardiotoxic	JJ	O
,	,	B
and	CC	I
US	NNP	O
patents	NNS	O
are	VBP	B
held	VBN	O
by	IN	O
the	DT	B
University	NNP	O
of	IN	B
Vermont	NNP	O
.	.	O

